The significance of ras activity in pancreatic cancer initiation

International Journal of Biological Sciences

Volumn 12, Issue 3, 2016, Pages 338-346

  Logsdon, Craig D ^a   Lu, Weiqin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

K Ras

Indexed keywords

PROTEIN P21;

ANIMAL; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY;

ANIMALS; HUMANS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84957591339     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.15020     Document Type: Review

References (50)

1. LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Woda C, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013; 19: 1047-53
2. Cox AD, Der CJ. Ras history: The saga continues. Small GTPases. 2010; 1: 2-27
3. Buday L, Downward J. Many faces of Ras activation. Biochim Biophys Acta. 2008; 1786: 178-87
4. Mitin N, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. Curr Biol. 2005; 15: R563-74
5. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010; 10: 842-57
6. Maertens O, Cichowski K. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv Biol Regul. 2014; 55: 1-14
7. Osterop AP, Medema RH, vd Zon GC, Bos JL, Moller W, Maassen JA. Epidermal-growth-factor receptors generate Ras.GTP more efficiently than insulin receptors. Eur J Biochem. 1993; 212: 477-82
8. Nicke B, Tseng MJ, Fenrich M, Logsdon CD. Adenovirus-mediated gene transfer of RasN17 inhibits specific CCK actions on pancreatic acinar cells. Am J Physiol. 1999; 276: G499-506
9. Holtz BJ, Lodewyk KB, Sebolt-Leopold JS, Ernst SA, Williams JA. ERK activation is required for CCK-mediated pancreatic adaptive growth in mice. Am J Physiol Gastrointest Liver Physiol. 2014; 307: G700-10
10. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, Daniluk J, et al. Ras Activity Levels Control the Development of Pancreatic Diseases. Gastroenterology. 2009
11. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003; 4: 437-50
12. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007; 11: 291-302
13. Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, et al. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest. 2012; 122: 1519-28
14. Carriere C, Young AL, Gunn JR, Longnecker DS, Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic K-Ras. Biochem Biophys Res Commun. 2009; 382: 561-5
15. Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, Gomez SB, et al. A High-Fat Diet Activates Oncogenic K-Ras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology. 2013
16. Yan L, McFaul C, Howes N, Leslie J, Lancaster G, Wong T, et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology. 2005; 128: 2124-30
17. Lu X, Xu T, Qian J, Wen X, Wu D. Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. Chin Med J (Engl). 2002; 115: 1632-6
18. Yakubovskaya MS, Spiegelman V, Luo FC, Malaev S, Salnev A, Zborovskaya I, et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer. 1995; 63: 810-4
19. Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology. 1996; 110: 227-31
20. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol. 2003; 16: 996-1006
21. Shi C, Hong SM, Lim P, Kamiyama H, Khan M, Anders RA, et al. K-RAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res. 2009; 7: 230-6
22. Delire B, Starkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest. 2015; 45: 609-23
23. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, et al. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol. 2011; 54: 311-9
24. Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 2005; 121: 849-58
25. Huang H, Daniluk J, Liu Y, Chu J, Li Z, Ji B, et al. Oncogenic K-Ras requires activation for enhanced activity. Oncogene. 2013
26. Bossu P, Vanoni M, Wanke V, Cesaroni MP, Tropea F, Melillo G, et al. A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts. Oncogene. 2000; 19: 2147-54
27. Almendro V, Garcia-Recio S, Gascon P. Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr Drug Targets. 2010; 11: 1169-80
28. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003; 284: 2-13
29. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, et al. EGF receptor is required for K-RAS-induced pancreatic tumorigenesis. Cancer Cell. 2012; 22: 304-17
30. Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 22: 318-30
31. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol. 2012; 13: 39-51
32. Holstein SA, Hohl RJ. Is there a future for prenyltransferase inhibitors in cancer therapy? Curr Opin Pharmacol. 2012; 12: 704-9
33. Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Molecular cell. 2006; 21: 481-93
34. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res. 2012; 22: 399-412
35. Sasaki AT, Carracedo A, Locasale JW, Anastasiou D, Takeuchi K, Kahoud ER, et al. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Signal. 2011; 4: ra13
36. Baker R, Wilkerson EM, Sumita K, Isom DG, Sasaki AT, Dohlman HG, et al. Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination. J Biol Chem. 2013; 288: 36856-62
37. Pfleger CM. Ubiquitin on ras: warden or partner in crime? Sci Signal. 2011; 4: pe12
38. Yang MH, Laurent G, Bause AS, Spang R, German N, Haigis MC, et al. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol Cancer Res. 2013; 11: 1072-7
39. Lander HM, Ogiste JS, Teng KK, Novogrodsky A. p21ras as a common signaling target of reactive free radicals and cellular redox stress. J Biol Chem. 1995; 270: 21195-8
40. Lander HM, Milbank AJ, Tauras JM, Hajjar DP, Hempstead BL, Schwartz GD, et al. Redox regulation of cell signalling. Nature. 1996; 381: 380-1
41. Heo J. Redox control of GTPases: from molecular mechanisms to functional significance in health and disease. Antioxidants & redox signaling. 2011; 14: 689-724
42. Ferro E, Goitre L, Retta SF, Trabalzini L. The Interplay between ROS and Ras GTPases: Physiological and Pathological Implications. J Signal Transduct. 2012: 365769
43. Heo J, Campbell SL. Superoxide anion radical modulates the activity of Ras and Ras-related GTPases by a radical-based mechanism similar to that of nitric oxide. The Journal of biological chemistry. 2005; 280: 12438-45
44. Santos E, Nebreda AR, Bryan T, Kempner ES. Oligomeric structure of p21 ras proteins as determined by radiation inactivation. J Biol Chem. 1988; 263: 9853-8
45. Guldenhaupt J, Rudack T, Bachler P, Mann D, Triola G, Waldmann H, et al. N-Ras forms dimers at POPC membranes. Biophys J. 2012; 103: 1585-93
46. Lin WC, Iversen L, Tu HL, Rhodes C, Christensen SM, Iwig JS, et al. H-Ras forms dimers on membrane surfaces via a protein-protein interface. Proc Natl Acad Sci U S A. 2014; 111: 2996-3001
47. Thompson H. US National Cancer Institute's new Ras project targets an old foe. Nat Med. 2013; 19: 949-50
48. Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, et al. Wildtype K-Ras2 can inhibit lung carcinogenesis in mice. Nature genetics. 2001; 29: 25-33
49. Cui XJ, He Q, Zhang JM, Fan HJ, Wen ZF, Qin YR. High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. Pancreas. 2014; 43: 135-40
50. Stan SD, Singh SV, Brand RE. Chemoprevention strategies for pancreatic cancer. Nature reviews Gastroenterology & hepatology. 2010; 7: 347-56.